Cleveland Clinic researchers have found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer ...

Johns Hopkins University cancer researcher Mikala Egeblad has received the 2025 Ernst W. Bertner Memorial Award in ...

A Rutgers-led study in Science Advances found low-protein diets slowed liver tumor growth and cancer death in mice, ...

Low baseline ctDNA levels in advanced breast cancer patients predict better response to targeted therapy and longer ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...

Company's shares hit all-time high after trial success Corcept plans to file US marketing application in third quarter Drug relacorilant may get broader label than competitors, analyst says March 31 ...

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to ...

Prostate cancer begins in the prostate, a small gland located just below the bladder, present only in people assigned male at birth (AMAB). This gland is in charge of producing seminal fluid, and it ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

Let's just say it takes longer to finish a Netflix episode.